The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000936325p
Ethics application status
Help: Ethics application status
Submitted, not yet approved
Date submitted
Help: Date submitted
6/07/2026
Date registered
Help: Date registered
29/07/2026
Date last updated
Help: Date last updated
29/07/2026
Date data sharing statement initially provided
Help: Data sharing statement date
29/07/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Validation of Biobeat Wearable Patch for Blood Pressure Monitoring in Pregnant Women
Scientific title
Validation of Biobeat Wearable Patch for Blood Pressure Monitoring in Pregnant Women Greater than 24 Weeks Gestation with and without Hypertensive Disorders of Pregnancy (HDP)
Additional trial identifiers [1] 317789 0
Nil
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Hypertensive Disorders of Pregnancy 342701 0
Condition category
Condition code
Reproductive Health and Childbirth 338842 338842 0 0
Antenatal care
Cardiovascular 338982 338982 0 0
Hypertension

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
The intervention in this study is a cuffless wearable Blood Pressure (BP) monitoring patch which uses Photoplethysmography(PPG)-based monitoring to measure blood pressure. After consent, the Biobeat patch will be applied to the chest by an independent researcher involved in the research team, and initialized according to manufacturer’s instructions. Participants will then undergo continuous BP monitoring for 3 days, after which the patch will be removed. If a participant undergoes an emergency caesarean section during the study period, the patch will be removed prior to delivery.

The device being validated is the Biobeat Chest Patch, developed by Biobeat Technologies, which measures peripheral blood pressure. Biobeat Technologies will be donating the devices for use in this validation study. The device a 3cm x 3cm sensor which is applied using a 5cm x 5cm adhesive patch. Application of the patch is not expected to inconvenience participants in any way and participants can go about their day as normal. It does not make any noise and has an internal battery.

• Approved Name: 613WP
• Trade Name: Biobeat
• Manufacturer of Device: Bio-Beat Technologies
• Supplier of Device: Bio-Beat Technologies
• Approved Therapeutic Indications: Hypertension Management and Monitoring
• Known Adverse Events: Skin Irritation
• Known Contra-Indications or Warnings: None
• Size: 3 cm x 3 cm diameter sensor applied using a 5cm x 5cm adhesive patch

This device will only be applied to pregnant women >24 weeks who are inpatients under the Monash Obstetrics team at Monash Medical Centre. Adherence will be monitored using data completeness.
Intervention code [1] 334633 0
Treatment: Devices
Description of the comparator or control
Each patient will act as their own control. Since the device will not replace standard care (blood pressure monitoring using an automatically inflating cuff or a sphygmomanometer and stethoscope), the blood pressure readings obtained from the Biobeat cuffless device will be compared to time-matched readings obtained using standard care. Standard care will be administered as deemed appropriate by the treating clinical team. Researchers themselves will not be administering standard care and this will be done solely by the clinical team.
Control group
Active

Outcomes
Primary outcome [1] 346049 0
Blood Pressure
Timepoint [1] 346049 0
Continuously throughout the use of the Biobeat wearable blood pressure patch
Secondary outcome [1] 464438 0
Nil
Timepoint [1] 464438 0
Nil

Eligibility
Key inclusion criteria
Females >18 years old who are >24 weeks gestation and are inpatients under Monash Maternity at Monash Medical Centre Clayton

Expected to be hospitalised and clinically stable for at least 72 hours
Minimum age
18 Years
Maximum age
No limit
Sex
Females
Healthy volunteers
No
Key exclusion criteria
• Unable to give informed consent
• Significant pre-existing arrhythmia
• Pre-existing dermatological or allergic conditions
• Clinically unstable:
o Signs of imminent delivery
o Presence of life-threatening bleeding
o Abnormal cardiotocography
o Needing emergency intervention
o Severe hypertension (Systolic BP greater than or equal to 160mmHg and/or Diastolic BP greater than or equal to 110mmHg)
o Hypertensive crisis requiring immediate intravenous antihypertensive treatment

Study design
Purpose of the study
Diagnosis
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis
Descriptive statistics will be used to summarise baseline characteristics, and proportions of primary and secondary outcomes. Continuous variables will be reported as means and standard deviations for normally distributed data and medians and interquartile ranges for non-normally distributed data. Categorical variables will be presented as percentages.
Time-matched paired measurements between Biobeat versus the reference blood pressure measurements, with a prespecified pairing window (e.g., closest Biobeat output within ±5 minutes of each standardized cuff reading) will be evaluated.
Agreement between measurement techniques will also be quantified separately for systolic and diastolic BPs by estimating mean BP difference (test versus reference) and standard deviation of the differences.[11]
To aid clinical interpretability, we will also report the proportion of absolute differences (Biobeat - reference) that fall within 5, 10, and 15 mmHg for SBP and DBP. Agreement will be visualised using standardised Bland–Altman plots, displaying the difference (Biobeat - reference) against the mean of the two methods, with the mean difference and 95% limits of agreement presented. Given the small sample size, there may be limited participant-level precision and within-subject correlation, which is a limitation of this study.
Subgroup analyses will also be undertaken between HDP and non-HDP participants. Given the small sample size, these analyses will be considered exploratory only.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 29801 0
Monash Medical Centre - Clayton campus - Clayton
Recruitment postcode(s) [1] 46147 0
3168 - Clayton

Funding & Sponsors
Funding source category [1] 322335 0
Commercial sector/Industry
Name [1] 322335 0
Biobeat Technologies
Country [1] 322335 0
Australia
Primary sponsor type
Individual
Name
Professor Kirsten Palmer , Monash Centre for Health Research and Implementation
Address
Country
Australia
Secondary sponsor category [1] 325252 0
Hospital
Name [1] 325252 0
Monash Health
Address [1] 325252 0
Country [1] 325252 0
Australia

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 320838 0
Monash Health Human Research Ethics Committee A
Ethics committee address [1] 320838 0
Ethics committee country [1] 320838 0
Australia
Date submitted for ethics approval [1] 320838 0
22/07/2026
Approval date [1] 320838 0
Ethics approval number [1] 320838 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 151794 0
Dr Jennifer Yo
Address 151794 0
Monash Health Department of Nephrology, 246 Clayton Road, Clayton 3168, Victoria
Country 151794 0
Australia
Phone 151794 0
+6139594 4820
Fax 151794 0
Email 151794 0
Contact person for public queries
Name 151795 0
Jennifer Yo
Address 151795 0
Monash Health Department of Nephrology, 246 Clayton Road, Clayton 3168, Victoria
Country 151795 0
Australia
Phone 151795 0
+6139594 4820
Fax 151795 0
Email 151795 0
Contact person for scientific queries
Name 151796 0
Jennifer Yo
Address 151796 0
Monash Health Department of Nephrology, 246 Clayton Road, Clayton 3168, Victoria
Country 151796 0
Australia
Phone 151796 0
+6139594 4820
Fax 151796 0
Email 151796 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: as per protocol, not required



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.